Insitro Funding History
Insitro applies machine learning to high-throughput human biology data for drug discovery and development.
Company Overview
Founded 2018 · South San Francisco, California, US
Official WebsiteInsitro Funding Timeline
Series C
US$400 million
Paul McCracken, a senior portfolio manager at CPP Investments, was set to join insitro’s board at the close.
Participation included Andreessen Horowitz, T. Rowe Price, BlackRock, ARCH Venture Partners, GV, Temasek.
Source · insitro.com ↗Series B
US$143 million
insitro said it would expand its machine-learning drug discovery platform and advance both internal and partnered therapeutic programs.
Led by Andreessen Horowitz. Participation included T. Rowe Price, BlackRock, ARCH Venture Partners, GV.
Source · biospace.com ↗
Insitro Founding Team
Insitro’s founding approach combined machine learning with large-scale experiments on human biology. The company applies that combination to finding and developing drugs.
- Daphne Koller — CEO. Stanford professor, Coursera co-founder and former Calico chief computing officer.
Insitro Company Development
Human Biology Data in Drug Discovery Partnerships
Insitro’s early collaboration with Gilead applied its human biology and machine learning approach to a specific liver disease. The collaboration shows how the company moved from building a data platform to applying it with a development partner in a defined indication.
Insitro Competitive Landscape
Experiment Design in AI Drug Discovery
Insitro trains models on high-throughput human biology data. Insilico Medicine also uses machine learning to identify targets, with a platform that explicitly extends into generative molecule design. The comparison turns on which evidence a drug discovery team needs to produce first.
